Provides broad coverage against canine distemper virus, canine adenovirus type 2 (CAV-2), and canine parvovirus (CPV)
Challenge studies in dogs showed 100% protection over 3 years against distemper, adenovirus type 1, and parvovirus10
Formulation containing CPV STRAIN 154®, able to override maternal antibodies at an early age1
Serologic tests demonstrated high antibody titers throughout the 3-year post-vaccination isolation period10
Manhattan strain of CAV-2 was used to confer protection against canine infectious hepatitis caused by canine adenovirus type 1 (CAV-1) without eliciting the adverse reactions associated with CAV-1 vaccines10
Protects against the commonly spread canine distemper virus
Protects against all field strains of CPV currently seen2
Prevents both infectious canine hepatitis caused by CAV-1 and infectious tracheobronchitis associated with CAV-2
INDICATIONS:
Approved for the vaccination of healthy dogs for the prevention of disease caused by canine distemper virus and canine parvovirus, and as an aid in the prevention of disease caused by canine adenovirus (both infectious canine hepatitis and infectious tracheobronchitis) for up to 3 years following initial and booster vaccinations.
Recommended for use in healthy dogs 7 weeks of age or older.
Efficacy & Comparisons
PROTECT AGAINST ALL KNOWN STRAINS OF CANINE PARVOVIRUS (CPV), INCLUDING CPV-2C
References 2,3,8
PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ2
No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains2
First published data showing protection against CPV-2c challenge2
All vaccinated puppies were protected from disease
All control puppies developed disease and 50% died or were euthanized
No items to show.
Loading…
CANINE 3-DAPV IS A SAFE CHOICE
Can be safely administered to dogs as young as 7 weeks of age
High-titer CPV and canine distemper virus strains proven safe for dogs as young as 4 weeks of age1
No injection site or vaccine-related reactions reported during challenge studies
ADMINISTRATION AND DOSAGE
Initial 1 mL dose given by subcutaneous route to healthy dogs as early as 7 weeks of age
1 mL booster doses given every 3 to 4 weeks until 12 weeks of age
Dogs over 12 weeks of age should initially receive 2 doses 3–4 weeks apart
Revaccination every 3 years with a single dose thereafter
2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101.
3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.
8. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1-2) :48-55.
10. Gore TC, Lakshmanan N, Duncan KL, Coyne ML, Lum MA, Sterner FJ. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus. Vet Ther. 2005;6(1):5–14
